We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Prenatal Cystic Fibrosis Tests Improve CFTR Screening Options

By LabMedica International staff writers
Posted on 03 Nov 2014
Print article
Image: The cystic fibrosis transmembrane conductance regulator (CFTR) channel protein controls the flow of H2O and Cl- ions into and out of lung cells. When CFTR is working correctly (Panel 1), these ions flow in and out. However, when CFTR is malfunctioning (as in Panel 2), these ions cannot flow out of the cell due to channel blockage, leading to the buildup of thick mucus in the lungs characteristic of cystic fibrosis (Photo courtesy of Wikimedia (user Lbudd14)).
Image: The cystic fibrosis transmembrane conductance regulator (CFTR) channel protein controls the flow of H2O and Cl- ions into and out of lung cells. When CFTR is working correctly (Panel 1), these ions flow in and out. However, when CFTR is malfunctioning (as in Panel 2), these ions cannot flow out of the cell due to channel blockage, leading to the buildup of thick mucus in the lungs characteristic of cystic fibrosis (Photo courtesy of Wikimedia (user Lbudd14)).
A new set of prenatal cystic fibrosis (CF) screening tests offer flexibility and comprehensiveness in screening for important CFTR gene variants.

Through its Institute for Biomarker Research division, Medical Diagnostic Laboratories, LLC (MDL; Hamilton, NJ, USA) is now offering a new CF testing option that utilizes cutting-edge technology, including next-generation sequencing (NGS) platforms. MDL, a member of the Genesis Biotechnology Group, is a CLIA-certified, CAP-accredited laboratory that specializes in high-complexity, state-of-the-art, automated DNA-based molecular analyses.

More than 1,800 different mutations have been discovered since the cystic fibrosis transmembrane conductance regulator (CFTR) gene responsible for CF (also called mucoviscidosis) was discovered in 1989. Offering CF carrier screening to all pregnant women as well as for preconception evaluation is now commonplace and formally recommended. Newborn screening for CF does not replace maternal-carrier screening. Screening is most efficacious in the non-Hispanic Caucasian and Ashkenazi Jewish populations.

Utilizing updated technologies, including NGS, MDL offers a diverse panel with high accuracy genetic testing that provides noninvasive, easy specimen collection methods for CF testing using mouthwash samples or cervico-vaginal swabs. Blood is also an acceptable source.

The MDL "Cystic Fibrosis Core Test" is a CFTR gene sequence analysis that screens for the 23 major mutations recommended by the American College of Medical Genetics (ACMG) and the American College of Obstetricians and Gynecologists (ACOG). The MDL "Cystic Fibrosis Comprehensive Test" is an expanded analysis that screens for 191 CFTR gene variants, including the recommended 23 major mutations and the 9 mutations recommended by the US Food and Drug Association (FDA) for determining Ivacaftor (Kalydeco) treatment efficiency. The MDL "Cystic Fibrosis Site Specific Analysis" screens for known family CF mutations previously identified in blood relatives.

Related Links:

Medical Diagnostic Laboratories


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.